Teva Establishes Four Pillars To Prop Up Its Return-To-Growth Strategy
Austedo And Uzedy Key To Near-Term Growth
Executive Summary
New CEO Richard Francis outlined the company’s new focus on innovative brands, funded by a portion of capital reallocated from Teva’s generics business.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.
Francis Takes Stock Of Teva Ahead Of Revealing Fresh Strategy
As Teva prepares to unveil a fresh strategy under new CEO Richard Francis on 18 May, the company has delivered Q1 results along with an update on planned US launches for long-acting injectable risperidone as well as biosimilar adalimumab.
AbbVie Broadens Qulipta Migraine Indication As Anti-CGRP Competition Grows
AbbVie’s migraine franchise expanded with US FDA approval of Qulipta for chronic migraine prevention, but its CGRP inhibitors are facing off against a pair of rivals acquired by Pfizer last year.